Skip to content

Syndromic Aortopathies

TL;DR — Four syndromes dominate syndromic thoracic aortic disease, and they behave differently enough that lumping them is dangerous. Marfan syndrome (FBN1) is defined by aortic root aneurysm plus ectopia lentis; median survival rose from 48 years in 1972 to 72 years by 1993 — one of the largest documented survival gains in cardiovascular medicine, attributed to surgery, secular trends and partly to ascertainment (Silverman 1995, PMID 7810492). Loeys-Dietz syndrome (TGFBR1/2, SMAD3, TGFB2/3) adds arterial tortuosity and craniofacial signs and dissects earlier and at smaller diameters — mean age at death 26.0 years in the original NEJM series, and root dissection at ≤45 mm in low-BSA women with TGFBR2 mutations (Loeys 2006, PMID 16928994; Jondeau 2016, PMID 27879313). Vascular Ehlers-Danlos syndrome (COL3A1) is the outlier: vessels rupture without much preceding dilatation, median survival is 48 years, and — unlike LDS — operative mortality is high (Pepin 2000, PMID 10706896; Loeys 2006, PMID 16928994). Turner syndrome dissects at a mean age of 30.7 years versus 68 in the general female population, and body-size-indexed diameter is used because absolute diameter under-reads risk in short stature (Carlson 2007, PMID 17873120). The recurring open question is whether earlier operation in each genotype actually improves survival — the thresholds are registry-derived, not trial-derived.

Marfan syndrome (FBN1)

Genetics. MFS is autosomal dominant, age-related but highly penetrant, with substantial intrafamilial and interfamilial variability, caused by pathogenic variants in FBN1 encoding fibrillin-1 — a major structural ECM component supporting arteries, the perichondrium and ocular structures. Up to 25% of individuals with MFS have de novo variants (Milewicz 2021, PMID 34475413). The gene was identified by linkage of the fibrillin gene to the Marfan phenotype (θ = 0.00; LOD = 3.9) together with a de novo missense mutation in two sporadic patients (Dietz 1991, PMID 1852208).

Diagnostic criteria. The revised (Ghent II) nosology puts more weight on cardiovascular manifestations and makes aortic root aneurysm and ectopia lentis the two cardinal features. In the absence of family history, the presence of both is sufficient for unequivocal diagnosis. In the absence of either, diagnosis requires a bona fide FBN1 mutation or a combination of systemic manifestations scored on a new systemic score. Special provisions cover diagnosis in children and alternative diagnoses in adults (Loeys 2010, PMID 20591885). The revision was motivated by the fact that some prior criteria were insufficiently validated, were inapplicable in children, or required expensive specialised investigations — and by the recognition that an MFS label, correct or not, can be stigmatising and can restrict career and insurance options (Loeys 2010, PMID 20591885). Under Ghent II, FBN1 testing is not mandatory but carries greater diagnostic weight than before.

Cardinal features. The most prominent manifestations are asymptomatic aortic root aneurysms, aortic dissections, ectopia lentis, and skeletal abnormalities characterised by long-bone overgrowth (Milewicz 2021, PMID 34475413). Genetic testing is not always required for diagnosis but helps distinguish MFS from other HTAD syndromes presenting with similar skeletal features (Milewicz 2021, PMID 34475413).

Aortic phenotype and its trajectory. Untreated aortic root aneurysms progress to life-threatening acute dissection; management requires medical therapy to slow aneurysm growth and reduce dissection risk, plus routine surveillance by transthoracic echocardiography, CT or MRI to determine timing of prophylactic repair (Milewicz 2021, PMID 34475413). Notably, the Marfan aorta grows more slowly than the familial non-syndromic aorta — 0.10 cm/yr vs 0.21 cm/yr — but starts far earlier, with a mean presentation age of 27.4 years vs 58.2 years (Albornoz 2006, PMID 16996941). The danger is duration of exposure, not growth velocity.

Life-expectancy transformation. In 417 patients with a definite MFS diagnosis from four referral centres, 47 died. Mean age at death rose from 32 ± 16 years (1972 data) to 41 ± 18 years (p = 0.0023), and median cumulative probability of survival rose from 48 years in 1972 to 72 years in 1993 — an increase of more than 25% (Silverman 1995, PMID 7810492).

Metric 1972 1993
Mean age at death 32 ± 16 y 41 ± 18 y
Median cumulative survival 48 y 72 y

Among 112 surgically treated patients, 10-year survival probability was 70%, and patients operated after 1980 had significantly better survival than those operated before 1980 (p = 0.008). Beta-blocker therapy was also associated with increased probable survival. The authors attributed the gain to three causes — general population life-expectancy improvement, cardiovascular surgery, and a greater proportion of mild cases entering the denominator as diagnosis became more frequent (Silverman 1995, PMID 7810492). That third mechanism is a real ascertainment caveat, not a footnote: some of the apparent gain is denominator change.

For pharmacotherapy (beta-blockers, ARBs) see medical therapy; for valve-sparing root replacement see surgical and endovascular repair.

Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3)

Discovery. Heterozygous mutations in the genes encoding TGF-β receptor types I and II were reported in ten families with a new phenotype spanning cardiovascular, craniofacial, neurocognitive and skeletal development. Paradoxically, although receptors from selected mutant alleles could not support TGF-β signal propagation, affected tissues showed increased collagen and connective tissue growth factor expression and nuclear enrichment of phosphorylated Smad2 — i.e. increased TGF-β signalling (Loeys 2005, PMID 15731757). This paradox is the origin of the field's central mechanistic dispute; see pathophysiology.

The defining triad and its natural history. LDS is characterised by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. In 52 affected families — 40 probands with typical LDS, plus a screen of 40 patients labelled vascular EDS who lacked type III collagen abnormalities and LDS craniofacial features — a TGFBR1 or TGFBR2 mutation was found in all typical LDS probands (type I) and in 12 of 40 of the vEDS-like probands (LDS type II). The natural history of both types was aggressive arterial aneurysm with mean age at death 26.0 years, and pregnancy-related complications in 6 of 12 women (Loeys 2006, PMID 16928994).

LDS type I LDS type II
Mean age at first cardiovascular surgery 16.9 y 26.9 y
Mean age at death 22.6 y 31.8 y

Severity of clinical presentation predicted outcome. Across 59 vascular surgeries in the cohort there was one intraoperative death — a low operative mortality that the authors used explicitly to distinguish LDS from vascular EDS and to argue for prophylactic vascular surgery in LDS (Loeys 2006, PMID 16928994). This is the key operative asymmetry between the two syndromes.

Gene-specific risk within LDS: the Montalcino registry. In 441 patients from 228 families (176 TGFBR1, 265 TGFBR2) across 15 specialist centres, survival was 80% at 60 years; 23% had an aortic dissection and 18% underwent preventive aortic surgery. Extra-aortic features were common: 29% hypertelorism, 53% cervical arterial tortuosity, 27% wide scars. TGFBR1 and TGFBR2 carriers had similar systemic-feature prevalence and similar global survival, but TGFBR1 males had greater aortic risk than TGFBR1 females, whereas TGFBR2 males and females were similar. Root diameter at or before type A dissection tended to be smaller in TGFBR2 carriers and was ≤45 mm in 6 women with marked systemic features and low body surface area. The consortium proposed preventive aortic surgery at 45 mm, lowered toward 40 mm in females with low BSA, TGFBR2 mutation and severe extra-aortic features. Aortic dissection complicated 1.6% of pregnancies (Jondeau 2016, PMID 27879313).

SMAD3 — aneurysms-osteoarthritis syndrome (LDS type 3). Screening 393 aneurysm patients without FBN1/TGFBR1/TGFBR2 mutations identified five novel SMAD3 mutations in five new families; combined with three previously described families, 45 patients across 8 families with 8 mutations were characterised. In the majority, early-onset joint disease — osteoarthritis and osteochondritis dissecans — was the presenting complaint for which medical advice was first sought. Cardiovascular abnormalities were present in nearly 90%, chiefly aortic aneurysm and dissection, with aneurysms and tortuosity found throughout the arterial tree including intracranial arteries. Of patients who first presented with joint abnormalities, 20% died suddenly of aortic dissection (van de Laar 2012, PMID 22167769). Mild craniofacial features — hypertelorism, abnormal uvula — aid recognition. The lesson is that the referral pathway is orthopaedic, and the fatal problem is aortic.

TGFB2. Heterozygous mutations or deletions in the TGF-β2 ligand produce a phenotype within the LDS spectrum, with upregulated TGF-β signalling in aortic tissue from affected individuals. Tgfb2+/− mice develop aortic root aneurysm with increased canonical and non-canonical TGF-β signalling, and mice carrying both a Marfan allele (Fbn1^C1039G/+) and Tgfb2 haploinsufficiency show phenotypic worsening alongside high TGF-β1 expression — supporting compensatory autocrine/paracrine contributions to pathogenesis (Lindsay 2012, PMID 22772368). An independent family with a 1-bp TGFB2 duplication (c.1165dupA, p.Ser389Lysfs*8) presented with aortic aneurysm, cervical arterial tortuosity, skeletal abnormalities and craniofacial dysmorphism, with the authors judging the clinical picture to fit LDS rather than MFS-related disorders; TGFB2 was a rarely mutated gene in their cohort of 88 Marfan-like/TAAD index cases (Leutermann 2013, PMID 24193348).

TGFB3. Across 470 index cases with thoracic aortic aneurysm, 43 patients from 11 families had syndromic aortic aneurysms caused by TGFB3 mutations. Cardiovascular involvement was significant — thoracic and abdominal aortic aneurysm and dissection, plus mitral valve disease. Systemic features overlapped Loeys-Dietz, Shprintzen-Goldberg and Marfan syndromes: cleft palate, bifid uvula, skeletal overgrowth, cervical spine instability and clubfoot deformity. As with TGFBR1/2, SMAD3 and TGFB2, aortic wall tissue showed paradoxical upregulation of both canonical and non-canonical TGF-β signalling alongside increased TGF-β ligand expression (Bertoli-Avella 2015, PMID 25835445).

Why earlier thresholds. Three independent observations converge: mean age at death of 26.0 years in the original series (Loeys 2006, PMID 16928994); dissection at root diameters ≤45 mm in TGFBR2 women (Jondeau 2016, PMID 27879313); and low operative mortality making prophylactic surgery comparatively cheap (Loeys 2006, PMID 16928994). See risk stratification and size thresholds and guidelines.

Vascular Ehlers-Danlos syndrome (COL3A1)

vEDS results from mutations in the gene for type III procollagen (COL3A1), placing patients at risk of arterial, bowel and uterine rupture. In the defining series of 220 index patients with biochemically confirmed disease plus 199 affected relatives — with the underlying COL3A1 mutation identified in 135 index patients — the natural history was quantified (Pepin 2000, PMID 10706896):

Outcome Figure
First complication by age 20 25% of index patients
At least one complication by age 40 > 80%
Median survival, whole cohort 48 years
Leading cause of death Arterial rupture
Bowel rupture ~25% of complications, often sigmoid colon; rarely fatal
Death from pregnancy complications 12 of 81 women who became pregnant

Complications were rare in childhood. Critically, the types of complications were not associated with specific mutations in COL3A1 — genotype does not forecast which organ fails (Pepin 2000, PMID 10706896).

Fragility without dilatation, and surgical risk. The diagnostic and management problem in vEDS is that vessels rupture without necessarily passing through a measurable aneurysmal phase, so diameter-based surveillance has limited purchase. The authors recommended considering the diagnosis in young people presenting with uterine rupture in pregnancy or arterial/visceral rupture (Pepin 2000, PMID 10706896). Operative risk is the second differentiator: the LDS cohort's low intraoperative mortality (1 death in 59 vascular surgeries) was explicitly framed as distinguishing LDS from vascular EDS, where operating on friable vessels is itself hazardous (Loeys 2006, PMID 16928994).

Nosology. vEDS is one of 13 subtypes recognised in the 2017 International Classification of the Ehlers-Danlos syndromes, which replaced the 1998 Villefranche six-subtype nosology. For all subtypes except hypermobile EDS, definitive diagnosis relies on molecular confirmation with identification of causative genetic variant(s), given the vast genetic heterogeneity, phenotypic variability, and clinical overlap between EDS subtypes and with other heritable connective tissue disorders (Malfait 2017, PMID 28306229).

Phenocopy warning. A clinical label of vEDS is not reliable: of 40 patients diagnosed with vascular EDS but lacking characteristic type III collagen abnormalities and LDS craniofacial features, 12 carried TGFBR1 or TGFBR2 mutations (Loeys 2006, PMID 16928994). Because the two syndromes have opposite surgical risk profiles, this misclassification is directly consequential — genotyping patients presenting with vEDS-like symptoms was recommended to guide therapy including the use and timing of prophylactic vascular surgery (Loeys 2006, PMID 16928994).

Turner syndrome aortopathy

Turner syndrome (TS) affects more than 50,000 girls and women in the United States (Bolar 2008, PMID 18000090). Girls and women with TS are at risk of catastrophic aortic dissection and rupture, but the at-risk clinical profile is poorly characterised.

Age and risk-factor profile. In a review of 85 reported cases of aortic dissection in TS published 1961–2006 plus two new cases, dissection occurred at a mean age of 30.7 years (range 4–64) — dramatically earlier than in the general female population, where it occurs at a mean of 68 years. Among cases in which hypertension (HTN) and congenital heart disease (CHD) were explicitly assessed (Carlson 2007, PMID 17873120):

Risk factor profile Proportion
HTN alone 15%
CHD alone 30%
Both HTN and CHD 34%
Neither identified 11%

The 11% with neither risk factor argues that TS itself is an independent risk factor for aortic dissection, though the authors cautioned that those cases were very poorly documented. Dissection in women with TS undergoing assisted reproductive techniques frequently resulted in death (Carlson 2007, PMID 17873120). In a separate long-term safety cohort of 5,220 TS children treated with recombinant human growth hormone, seven deaths occurred, five from aortic dissection or rupture; the incidence was judged to reflect the higher baseline aortic risk in TS rather than a drug effect (Bolar 2008, PMID 18000090).

Aortic size index (ASI). Because TS involves short stature, absolute aortic diameter systematically understates risk, and ASI — aortic diameter indexed to body surface area — has been proposed as a more reliable criterion, with thresholds in the range 20–25 mm/m². The index is not, however, safe as a sole discriminator: an aortic arch dissection has been reported in a TS patient whose ASI placed her in the low-risk band and who was therefore not offered prophylactic surgery, prompting the recommendation that careful monitoring and surgical evaluation proceed even at ASI < 20 mm/m² when other significant risk factors are present (Nijs 2014, PMID 24944765). This is a single case report and should be weighted as such, but it identifies the failure mode of any indexed threshold used alone.

The evidence problem. The literature on aortic dissection in TS is sparse and most cases are poorly documented, making firm monitoring and treatment guidelines difficult to establish; a TS aortic dissection registry was established for this reason (Carlson 2007, PMID 17873120). Bicuspid aortic valve is a frequent co-occurring lesion in TS — see bicuspid aortopathy.

Arterial tortuosity syndrome (SLC2A10)

ATS is an autosomal recessive disorder — the only recessive condition in this page — characterised by tortuosity, elongation, stenosis and aneurysm formation in the major arteries, arising from disruption of elastic fibres in the medial layer of the arterial wall. Homozygosity mapping localised the locus to chromosome 20q13.1, and mutations in SLC2A10, encoding the facilitative glucose transporter GLUT10, were identified in six ATS families. GLUT10 deficiency is associated with upregulation of the TGF-β pathway in the arterial wall — the same finding as in Loeys-Dietz syndrome, where aortic aneurysm also associates with arterial tortuosity (Coucke 2006, PMID 16550171). The convergence of a glucose transporter on the TGF-β aortopathy phenotype remains mechanistically unexplained and is one of the odder results in the field.

Cross-syndrome comparison

Syndrome Gene(s) Inheritance Aortic behaviour Key survival figure
Marfan FBN1 AD, ≤25% de novo Root aneurysm, slow growth (0.10 cm/yr), early onset (mean 27.4 y) Median survival 72 y (1993) vs 48 y (1972)
Loeys-Dietz TGFBR1/2, SMAD3, TGFB2/3 AD Aggressive, widespread, tortuous; dissection at smaller diameters Mean age at death 26.0 y (2006 series); 80% survival at 60 y (2016 registry)
Vascular EDS COL3A1 AD Rupture without much dilatation; arterial, bowel, uterine Median survival 48 y
Turner 45,X and variants Chromosomal Dissection at young age; frequent BAV/coarctation Mean age at dissection 30.7 y vs 68 y general female population
Arterial tortuosity SLC2A10 AR Generalised tortuosity, elongation, stenosis, aneurysm Not established in the cited source

Open questions

  • Do lowered LDS thresholds actually save lives? The 45 mm / 40 mm recommendations rest on retrospective observation of 6 TGFBR2 women who dissected at ≤45 mm out of 441 registry patients (Jondeau 2016, PMID 27879313). No prospective comparison of threshold strategies exists, so the number needed to operate — and the cost in unnecessary root replacements — is unquantified.
  • How much of Marfan's survival gain is real versus ascertainment? Silverman explicitly listed "greater proportion of milder cases due to increased frequency of diagnosis" as one of three candidate explanations alongside surgery and secular life-expectancy trends (Silverman 1995, PMID 7810492). The relative contributions were not partitioned, and the study predates the modern ARB era.
  • Why is TGF-β signalling increased when the mutations are loss-of-function? Receptor alleles that cannot propagate TGF-β signal nonetheless produce tissue evidence of increased signalling (Loeys 2005, PMID 15731757), and TGFB2 haploinsufficiency raises signalling and worsens the Fbn1 phenotype (Lindsay 2012, PMID 22772368). Whether the excess signalling is driver or compensation is unresolved.
  • What predicts which organ ruptures in vEDS? Complication type showed no association with specific COL3A1 mutations (Pepin 2000, PMID 10706896), so no genotype-based triage of arterial vs bowel vs uterine risk is currently possible.
  • Is any indexed threshold adequate in Turner syndrome? ASI thresholds of 20–25 mm/m² are proposed, yet dissection has occurred below 20 mm/m² (Nijs 2014, PMID 24944765), and the underlying literature is sparse and poorly documented (Carlson 2007, PMID 17873120).
  • How does a glucose transporter cause a TGF-β aortopathy? GLUT10 deficiency upregulates arterial-wall TGF-β signalling (Coucke 2006, PMID 16550171) by a mechanism that has not been established.

References

  1. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-9. PMID 1852208
  2. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47:476-85. PMID 20591885
  3. Milewicz DM, Braverman AC, De Backer J, et al. Marfan syndrome. Nat Rev Dis Primers. 2021;7:64. PMID 34475413
  4. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75:157-60. PMID 7810492
  5. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37:275-81. PMID 15731757
  6. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788-98. PMID 16928994
  7. Jondeau G, Ropers J, Regalado E, et al. International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet. 2016;9:548-558. PMID 27879313
  8. van de Laar IMBH, van der Linde D, Oei EHG, et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet. 2012;49:47-57. PMID 22167769
  9. Lindsay ME, Schepers D, Bolar NA, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet. 2012;44:922-7. PMID 22772368
  10. Leutermann R, Sheikhzadeh S, Brockstädt L, et al. A 1-bp duplication in TGFB2 in three family members with a syndromic form of thoracic aortic aneurysm. Eur J Hum Genet. 2013;22:944-8. PMID 24193348
  11. Bertoli-Avella AM, Gillis E, Morisaki H, et al. Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol. 2015;65:1324-1336. PMID 25835445
  12. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673-80. PMID 10706896
  13. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8-26. PMID 28306229
  14. Carlson M, Silberbach M. Dissection of the aorta in Turner syndrome: two cases and review of 85 cases in the literature. J Med Genet. 2007;44:745-9. PMID 17873120
  15. Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab. 2008;93:344-51. PMID 18000090
  16. Nijs J, Gelsomino S, Lucà F, et al. Unreliability of aortic size index to predict risk of aortic dissection in a patient with Turner syndrome. World J Cardiol. 2014;6:349-52. PMID 24944765
  17. Coucke PJ, Willaert A, Wessels MW, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38:452-7. PMID 16550171
  18. Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections — incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg. 2006;82:1400-5. PMID 16996941